相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The Future of Somatostatin Receptor Ligands in Acromegaly
Monica R. Gadelha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Diagnosis and Treatment of Acromegaly: An Update
Nazanin Ershadinia et al.
MAYO CLINIC PROCEEDINGS (2022)
Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly
Amy A. Swanson et al.
PITUITARY (2021)
A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu et al.
PITUITARY (2021)
Predictors of postoperative biochemical remission in acromegaly
Shun Yao et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas
Marta Araujo-Castro et al.
ENDOCRINE CONNECTIONS (2021)
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling
Erika Peverelli et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Impact of Experience on Outcomes After Endoscopic Transsphenoidal Surgery for Acromegaly
Abhijit Goyal-Honavar et al.
WORLD NEUROSURGERY (2021)
Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time
Alireza Ghajar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas
Alev Selek et al.
GROWTH HORMONE & IGF RESEARCH (2019)
The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly
Ozge Polat Korkmaz et al.
PITUITARY (2019)
Local myofascitis: An unusual adverse reaction to lanreotide autogel injection
Mirella Hage et al.
ANNALES D ENDOCRINOLOGIE (2019)
Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies
Chengxian Yang et al.
SCIENTIFIC REPORTS (2019)
Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience
Liang Lv et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly
F. Albarel et al.
PITUITARY (2018)
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
Luigi Maione et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Effects of anti-somatostatin agents on glucose metabolism
B. Verges
DIABETES & METABOLISM (2017)
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
Kjell Oberg et al.
ENDOCRINE-RELATED CANCER (2016)
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Iulia Potorac et al.
ENDOCRINE-RELATED CANCER (2016)
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
Ansgar Heck et al.
ENDOCRINE (2016)
Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis
Lei Zhang et al.
BRAIN & DEVELOPMENT (2015)
Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system
V. S. Nunes et al.
PITUITARY (2015)
Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?
Jubbin J. Jacob et al.
CLINICAL ENDOCRINOLOGY (2014)
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Philippe J. Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients
Frederique Albarel et al.
CLINICAL ENDOCRINOLOGY (2013)
A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
Anand K. Annamalai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
Olivera Casar-Borota et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
Francisco Pita-Gutierrez et al.
PLOS ONE (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma
Z-Q Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study
Ming Shen et al.
ENDOCRINE JOURNAL (2010)
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial
Zhi-gang Mao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Andrea Giustina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
V. J. Moyes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly
B. Steffin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Presurgical treatment with somatostatin analogs in patients with acromegaly:: effects on the remission and complication rates
M Losa et al.
JOURNAL OF NEUROSURGERY (2006)
Perioperative management of patients undergoing transsphenoidal pituitary surgery
EC Nemergut et al.
ANESTHESIA AND ANALGESIA (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Presurgical octreotide treatment in acromegaly:: no improvement of final growth hormone (GH) concentration and pituitary function.: A long-term case-control study
U Plöckinger et al.
ACTA NEUROCHIRURGICA (2005)
Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
Roberto Baldelli et al.
CLINICAL ENDOCRINOLOGY (2003)
How effective are current therapies for acromegaly?
PU Freda
GROWTH HORMONE & IGF RESEARCH (2003)
The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas
J Cap et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2003)
Preoperative lanreotide treatment for GH-secreting pituitary adenomas:: effect on tumour volume and predictive factors of significant tumour shrinkage
T Lucas et al.
CLINICAL ENDOCRINOLOGY (2003)
The role of pharmacotherapy in perioperative management of patients with acromegaly
A Ben-Shlomo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre
T Abe et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Dopamine D2 receptor gene expression in human adenohypophysial adenomas
L Stefaneanu et al.
ENDOCRINE (2001)
Difficult intubation in acromegalic patients -: Incidence and predictability
H Schmitt et al.
ANESTHESIOLOGY (2000)
Anaesthetic complications of acromegaly
PA Seidman et al.
BRITISH JOURNAL OF ANAESTHESIA (2000)